J Clin Med COVID-19 Related Coagulopathy: A Distinct Entity?

[tetano]

J Clin Med


. 2020 May 31;9(6):E1651.
doi: 10.3390/jcm9061651.
COVID-19 Related Coagulopathy: A Distinct Entity?


Benjamin Marchandot ¹ , Laurent Sattler ² , Laurence Jesel ^{1 3} , Kensuke Matsushita ^{1 3} , Valerie Schini-Kerth ³ , Lelia Grunebaum ² , Olivier Morel ^{1 3}



Affiliations

• PMID: 32486469
• DOI: 10.3390/jcm9061651

Free article

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy.

Keywords: COVID-19; antiphospholipid antibodies; coronavirus disease 2019; endothelium; hemostasis; microparticles; thrombosis.